company background image
PSNL

Personalis NasdaqGM:PSNL Stock Report

Last Price

US$3.68

Market Cap

US$167.2m

7D

8.2%

1Y

-86.1%

Updated

28 Jun, 2022

Data

Company Financials +
PSNL fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

PSNL Stock Overview

Personalis, Inc. operates as a cancer genomics company worldwide.

Personalis Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Personalis
Historical stock prices
Current Share PriceUS$3.68
52 Week HighUS$28.28
52 Week LowUS$3.13
Beta1.74
1 Month Change-19.65%
3 Month Change-55.77%
1 Year Change-86.06%
3 Year Change-84.08%
5 Year Changen/a
Change since IPO-87.08%

Recent News & Updates

Jun 16

The Prognosis For Personalis

Today, we profile Personalis, a small cancer genomics testing firm. The stock has taken a battering in 2022 and is posting substantial quarterly losses, but shares now sell for less than net cash. 2022 is a transition year for the company in many ways. An investment analysis follows in the paragraphs below.

Jun 09
Health Check: How Prudently Does Personalis (NASDAQ:PSNL) Use Debt?

Health Check: How Prudently Does Personalis (NASDAQ:PSNL) Use Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Shareholder Returns

PSNLUS Life SciencesUS Market
7D8.2%4.5%1.7%
1Y-86.1%-19.0%-20.4%

Return vs Industry: PSNL underperformed the US Life Sciences industry which returned -17.4% over the past year.

Return vs Market: PSNL underperformed the US Market which returned -18.8% over the past year.

Price Volatility

Is PSNL's price volatile compared to industry and market?
PSNL volatility
PSNL Average Weekly Movement14.1%
Life Sciences Industry Average Movement11.3%
Market Average Movement8.0%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.2%

Stable Share Price: PSNL is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: PSNL's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2011326John Westhttps://www.personalis.com

Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities.

Personalis Fundamentals Summary

How do Personalis's earnings and revenue compare to its market cap?
PSNL fundamental statistics
Market CapUS$167.24m
Earnings (TTM)-US$81.03m
Revenue (TTM)US$79.84m

2.1x

P/S Ratio

-2.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PSNL income statement (TTM)
RevenueUS$79.84m
Cost of RevenueUS$51.33m
Gross ProfitUS$28.51m
Other ExpensesUS$109.54m
Earnings-US$81.03m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.78
Gross Margin35.71%
Net Profit Margin-101.49%
Debt/Equity Ratio1.2%

How did PSNL perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is PSNL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PSNL?

Other financial metrics that can be useful for relative valuation.

PSNL key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Sales Ratio vs Peers

How does PSNL's PS Ratio compare to its peers?

PSNL PS Ratio vs Peers
The above table shows the PS ratio for PSNL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average7.5x
CGEN Compugen
25.9x89.2%US$167.7m
CDXC ChromaDex
1.8x22.5%US$122.6m
LAB Standard BioTools
1.1xn/aUS$139.1m
HBIO Harvard Bioscience
1.3x11.7%US$155.5m
PSNL Personalis
2.1x28.2%US$167.2m

Price-To-Sales vs Peers: PSNL is good value based on its Price-To-Sales Ratio (2.1x) compared to the peer average (7.5x).


Price to Earnings Ratio vs Industry

How does PSNL's PE Ratio compare vs other companies in the US Life Sciences Industry?

Price-To-Sales vs Industry: PSNL is good value based on its Price-To-Sales Ratio (2.1x) compared to the US Life Sciences industry average (5.2x)


Price to Sales Ratio vs Fair Ratio

What is PSNL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PSNL PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.1x
Fair PS Ratio4.7x

Price-To-Sales vs Fair Ratio: PSNL is good value based on its Price-To-Sales Ratio (2.1x) compared to the estimated Fair Price-To-Sales Ratio (4.7x).


Share Price vs Fair Value

What is the Fair Price of PSNL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PSNL's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PSNL's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PSNL's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Personalis forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


1.2%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PSNL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PSNL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PSNL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PSNL's revenue (28.2% per year) is forecast to grow faster than the US market (8.3% per year).

High Growth Revenue: PSNL's revenue (28.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PSNL is forecast to be unprofitable in 3 years.


Discover growth companies

Past Performance

How has Personalis performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-36.6%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: PSNL is currently unprofitable.

Growing Profit Margin: PSNL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PSNL is unprofitable, and losses have increased over the past 5 years at a rate of 36.6% per year.

Accelerating Growth: Unable to compare PSNL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PSNL is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (21%).


Return on Equity

High ROE: PSNL has a negative Return on Equity (-28.26%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Personalis's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: PSNL's short term assets ($294.0M) exceed its short term liabilities ($39.8M).

Long Term Liabilities: PSNL's short term assets ($294.0M) exceed its long term liabilities ($54.1M).


Debt to Equity History and Analysis

Debt Level: PSNL has more cash than its total debt.

Reducing Debt: Insufficient data to determine if PSNL's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PSNL has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: PSNL has sufficient cash runway for 2.4 years if free cash flow continues to reduce at historical rates of 56.4% each year.


Discover healthy companies

Dividend

What is Personalis's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate PSNL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PSNL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PSNL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PSNL's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as PSNL has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.2yrs

Average management tenure


CEO

John West (64 yo)

10.83yrs

Tenure

US$4,929,200

Compensation

Mr. John Stephen West is Co-Founder of Personalis, Inc and has been its Chief Executive Officer since August 3, 2011. Mr. West has been President and Director of Personalis, Inc since August 2011. He has b...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD4.93M) is above average for companies of similar size in the US market ($USD1.75M).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: PSNL's management team is considered experienced (2.2 years average tenure).


Board Members

Experienced Board: PSNL's board of directors are considered experienced (3.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: PSNL insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.5%.


Top Shareholders

Company Information

Personalis, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Personalis, Inc.
  • Ticker: PSNL
  • Exchange: NasdaqGM
  • Founded: 2011
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$167.245m
  • Shares outstanding: 45.45m
  • Website: https://www.personalis.com

Number of Employees


Location

  • Personalis, Inc.
  • 1330 O’Brien Drive
  • Menlo Park
  • California
  • 94025
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/28 00:00
End of Day Share Price2022/06/28 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.